Author

D. Montanari

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Advancing therapies for HER2-positive metastatic breast cancer: Navigating a wealth of treatment options.

The therapeutic landscape of HER2-positive metastatic breast cancer (HER2-positive mBC) has been transformed by increasingly effective HER2-directed therapies. Following the establishment of trastuzumab and pertuzumab as first-line standard treatment, highly active antibody-drug conjugates (ADCs), particularly trastuzu...

M. Palleschi, A. Viansone, Filippo Merloni et al. · Cancer Treatment Reviews · 0 citations

Open access Sep 2026

Prognostic value of hormone receptor expression in patients with HR+/HER2− advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study

Effectiveness of first-line ET plus CDK4/6i in patients with HR+/HER2− aBC worsens progressively with decreasing ERα expression, and PgR expression adds further prognostic discrimination, with low ERα and PgR expression identifying a subgroup of patients with particularly poor outcomes.

F. Ligorio, L. Provenzano, R. Caputo et al. · EClinicalMedicine · 0 citations